The pharmaceutical industry produces billions of oral solid dosage forms each year, and two formats do most of the heavy lifting: softgels and tablets. They need different equipment, different skills, and different budgets. The choice between them ripples through your entire operation. If you are a contract manufacturer or a pharma company adding capacity, the softgel encapsulation route and the tablet compression route lead to very different places.
Softgels work best for liquid or oil-based formulations that need rapid absorption and precise dosing. Tablets excel at high-volume production of stable, low-cost solid doses. The right pick comes down to your active ingredient’s chemistry, your target release profile, your budget, and the equipment you already own or plan to buy.
Here is how each format is made, what machines you need, how they stack up on cost and stability, and which one fits different production scenarios.
What are softgels and how they are made
Softgels are one-piece gelatin or non-gelatin shells filled with liquid, semi-solid, or suspension formulations. They are made on a rotary die encapsulation machine: two gelatin ribbons get sealed around the fill material in one continuous motion.
Softgel manufacturing steps
Softgel production has a few connected stages. First, you mix gelatin, plasticizers, and purified water in a heated tank to form the gel mass. The mixture melts and gets degassed, then feeds out as two continuous ribbons into the encapsulation machine. Fill material, usually an oil-based liquid or suspension, gets injected between the ribbons as they pass through rotating dies. The dies cut and seal in one motion, producing individual soft gels.
After encapsulation, the softgels need drying. If they are too wet, they stick together and leak. Too dry and they crack. Most facilities run them through tumble dryers first, then onto trays in climate-controlled rooms for final drying. Softgel drying takes 12 to 72 hours, depending on the shell formula and fill composition.
Dried softgels then go through inspection for leaks, misshapen units, and fill-weight variation. Some manufacturers run a polishing step to remove surface oil before packaging. Compared to tablet production, softgel manufacturing needs tighter control over humidity and temperature, especially during drying.
Equipment for softgel manufacturing
The centerpiece is a rotary die encapsulation machine, backed by gel melting tanks, mixers, a tumble dryer, drying trays, and inspection stations. If you want to enter the softgel market without building a full line from scratch, a common approach is to outsource the encapsulation step and handle drying and finishing in-house. As volumes grow, fully automated systems combine filling, sealing, drying, and inspection into one workflow.
What are tablets and how they are made
Tablets are compressed powder or granule blends made on a tablet press. Powder feeds into a die cavity, gets squeezed between two punches at high pressure, and a solid dose unit comes out in under a second.
Tablet manufacturing steps
Tablet production starts with the formula. You blend the active pharmaceutical ingredient (API) with excipients: fillers for bulk, binders to hold things together, disintegrants to break the tablet apart after swallowing, lubricants to stop the tablet from sticking in the die, and sometimes glidants for better powder flow. If the blend does not flow well or compress cleanly, it goes through granulation (wet or dry) before hitting the press.
The finished blend goes into the hopper of a tablet press. The press feeds powder into a die, compresses it between upper and lower punches, then ejects the tablet. A modern rotary press with dozens of stations cranks out hundreds of thousands of tablets per hour.
After compression, many tablets go to a coating pan. Film coating adds color and makes the tablet easier to swallow. Enteric coating delays release until the tablet hits the intestine. Sugar coating masks unpleasant tastes. Coated tablets then go through inspection for weight, thickness, hardness, and surface defects. Automated systems flag chipped edges, off-color tablets, and weight outliers in real time. A dedusting step clears loose powder before packaging.
Equipment for tablet manufacturing
The tablet press is the core machine. It comes in single-punch versions for R&D and small batches and rotary versions for production. Support equipment includes granulators, fluid bed or tray dryers, mills, blenders, a tablet coating machine, a deduster, and inspection gear. Compared to softgel lines, tablet equipment has a bigger secondhand market and more suppliers to choose from, which lowers the barrier to getting started.
Softgels vs Tablets: head-to-head comparison
Both formats have their place. The table below focuses on the factors production managers and business owners care about when they are evaluating an equipment investment.
| Factor | Softgels | Tablets |
|---|
| Formulation type | Oils, liquids, suspensions, pastes | Dry powders or granules |
| Production speed | 30,000-100,000 per hour (rotary die) | 100,000-1,000,000+ per hour (rotary press) |
| Equipment cost | Higher upfront, specialized | Lower entry cost, widely available |
| Drying time | 12-72 hours required | None (unless wet granulation used) |
| Stability sensitivity | High humidity and temperature matter a lot | Moderate; less affected by humidity |
| Dose uniformity | Excellent for low-dose APIs | Good; depends on blend uniformity |
| Bioavailability | Fast liquid fill absorbs quickly | Variable; depends on disintegration time |
| Taste masking | The shell is a natural barrier | Needs a coating step |
| Tooling changeover | Die roll replacement | Punch and die set replacement |
| Shelf life | 18-36 months typical | 24-60 months typical |
| Tamper evidence | Built-in; punctures are visible | Needs packaging for tamper evidence |
| Unit cost per dose | Higher | Lower |
Production speed and scale
At the high end, tablet presses run circles around softgel encapsulation machines. A 60-station rotary tablet press turns out more than 500,000 tablets per hour. The fastest rotary die softgel machines top out near 100,000 per hour. If you run high-volume generic lines, this speed gap pushes you toward tablets. But if your drug is a low-dose, oil-soluble compound that needs the bioavailability edge a softgel gives you, speed is not the only number that counts.
Equipment investment
A production-scale rotary die encapsulation line costs more than a tablet compression line at equivalent output. Softgel machinery means precision die tooling, gel melting systems, drying rooms, and tighter environmental control. Tablet lines are more modular: you can start with a press and add coating, dedusting, and inspection units as orders grow. The capsule filler market (hard capsules, not softgels) is another entry point with even lower equipment costs for small-batch producers.
Stability and shelf life
Tablets win on stability. The dry compression process leaves very little moisture in the finished product, so microbial growth and chemical breakdown are slow. Softgels have around 6-10 percent shell moisture, which means the fill formula must be designed carefully to stop water from migrating into the shell or shell components from leaching into the fill. That is why softgel products tend to have shorter shelf lives and tighter storage requirements. In contrast, softgels protect oxygen-sensitive fills better than uncoated tablets because the sealed shell is a strong oxygen barrier.
Bioavailability considerations
For APIs that do not dissolve well in water, softgels often beat tablets on bioavailability. The drug is already dissolved or suspended in a liquid inside the shell, so absorption starts the moment the shell ruptures in the stomach. Tablets have to disintegrate first, then dissolve. That extra step matters. This is the main reason formulators choose softgels for certain drugs even though manufacturing costs more.
Capsules as a middle ground
Hard capsules sit between softgels and tablets on the dosage-form spectrum. A capsule filling machine stuffs two-piece gelatin or HPMC shells with powders, pellets, granules, or even small tablets. Hard capsules disintegrate faster than tablets without the liquid-fill headaches and drying time of softgels.
If you already run tablet lines, adding a capsule filler grows your product range without the steep learning curve of softgel encapsulation. The machines are simpler, changeover is quicker, and the unit economics are between those of tablets and softgels. When your existing tablet customers start asking for capsule formats, empty capsules and a filler are the most practical next move.
Quality control and inspection across dosage forms
Every dosage form gets inspected, but the methods shift with the format. Tablet QC checks weight, thickness, hardness, friability, and surface defects like chipping or capping. Capsule QC checks for split shells, dented bodies, and weight variation. Softgel QC adds leak testing and fill-weight verification on top of visual checks. All three formats run through visual inspection stations, but the camera setups and rejection triggers are tuned to each format.
On tablet lines, automated optical inspection systems catch surface defects at full production speed. A capsule polisher does double duty on capsule lines: it clears dust and loose powder while letting operators spot visual flaws. In softgel production, inspection happens after drying, with operators hunting for leaks, shape problems, and fill variation.
Tablet coating: adding functionality and polish
Tablet coating turns a plain compressed tablet into a finished drug product. Film coating adds color, makes the tablet easier to swallow, and shields it from moisture and light. Enteric coating stops the tablet from dissolving in the stomach so it releases in the intestine. Sugar coating, less common now, still works well for taste masking.
Softgels skip coating entirely. The gelatin shell already gives you a smooth surface, built-in taste masking, and a moisture barrier. You save a processing step compared to coated tablets. But the shell is also a formulation variable you have to develop and validate, so the saved step is offset by extra work upstream.
How to choose: a decision framework
If you are putting together a new line or expanding an existing one, the questions below should narrow your options.
Formulation characteristics. Is your API an oil, a liquid, or a dry powder? Oils and liquids push you toward softgels. Dry powders work with both tablets and hard capsules. If your API is heat- or moisture-sensitive, tablets usually give you better stability.
Production volume. Are you making millions of units a month or hundreds of thousands? High-volume generics lean toward tablets. Niche nutraceuticals or specialized lipid-based drugs lean toward softgels.
Budget and timeline. Softgel equipment costs more and takes longer to commission. A tablet line can be up and running in weeks, not months, especially if you buy a press from a supplier with short lead times. If speed to market is your top concern, this gap is real.
Customer expectations. In some markets, consumers see softgels as premium and tablets as commodities. For others, tablets are the format people know and trust. Local market research should guide this part of the call.
Manufacturing capability. Softgels need know-how in gelatin handling, ribbon formation, fill formulation, and drying curves. If your team is comfortable with powder blending and compression but new to encapsulation, tablets or hard capsules are the safer place to start.
Regulatory considerations
Regulators treat softgels and tablets under similar quality frameworks, but the test panels are different. Tablets go through dissolution testing to confirm the drug releases on schedule. Softgels need rupture testing and sometimes dissolution testing too, plus extra checks for shell integrity and cross-linking. Cross-linking can slow dissolution in aged products, which draws additional scrutiny during stability review. If you plan to sell across multiple markets, confirm whether your target regulators impose any format-specific requirements that could drag out registration.
Cost breakdown over the product lifecycle
Upfront equipment cost is only part of the picture. Softgels carry higher per-unit manufacturing costs from raw materials (gelatin and plasticizers), longer cycle times (drying), and more involved QC. Tablets ride on cheaper raw materials (excipients), shorter cycle times, and simpler QC. Over the product’s full lifecycle, the unit-cost gap tightens a bit because softgel formulas often need less API per dose thanks to the bioavailability boost, but tablets stay cheaper for most applications.
For contract manufacturers, the math shifts. A capsule filler line or a tablet compression line serves a wider mix of client projects, so utilization stays higher and payback comes faster. Softgel lines are more specialized. They need a steady flow of liquid-fill projects to stay profitable.
Conclusion
Softgels and tablets are not really competing. They solve different problems. Softgels handle liquid formulations with strong bioavailability and precise dosing, all inside a sealed shell. Tablets crank out solid-dose products in enormous volume, with long shelf life, at the lowest cost per unit.
Your choice follows your drug’s chemistry, your production targets, your budget, and what your team knows how to run. For most facilities, the practical path is a tablet or capsule filling equipment line first, then softgel capability later as the portfolio and customer base expand.
Frequently asked questions
Can a tablet press also make softgels?
No. A tablet press compresses powders. Softgels are made on a rotary die encapsulator that seals liquid between two gelatin ribbons. The two formats share no common production equipment beyond support items like inspection systems and packaging machines.
How long does it take to switch a production line from tablets to softgels?
You cannot convert a tablet line into a softgel line. The equipment sets are entirely different. At the facility level, pulling tablet machines and installing softgel equipment means several months for procurement, installation, validation, and operator training.
Which dosage form has lower regulatory risk for a new generic product?
Tablets carry lower regulatory risk for generics. The bioequivalence pathway is well understood, and the dissolution testing framework is mature. Softgel generics face extra questions around shell formulation, cross-linking, and establishing an in vitro-in vivo correlation, which can stretch out approval timelines.
